TY - JOUR
T1 - A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity
AU - Rosa-Salazar, V.
AU - Trujillo-Santos, J.
AU - Díaz Peromingo, J. A.
AU - Apollonio, A.
AU - Sanz, O.
AU - Malý, R.
AU - Muñoz-Rodriguez, F. J.
AU - Serrano, J. C.
AU - Soler, S.
AU - Monreal, M.
AU - The RIETE Investigators
A2 - Decousus, H.
A2 - Prandoni, P.
A2 - Brenner, B.
A2 - Barba, R.
A2 - Di Micco, P.
A2 - Bertoletti, L.
A2 - Schellong, S.
A2 - Tzoran, I.
A2 - Reis, A.
A2 - Bosevski, M.
A2 - Bounameaux, H.
A2 - Wells, P.
A2 - Papadakis, M.
A2 - Adarraga, M. D.
A2 - Alibalic, A.
A2 - Alvarado-Faria, A.
A2 - Arcelus, J. I.
A2 - Auguet, T.
A2 - Ballaz, A.
A2 - Barrón, M.
A2 - Barrón-Andrés, B.
A2 - Bascuñana, J.
A2 - Benítez, J. F.
A2 - Blanco-Molina, A.
A2 - Bueso, T.
A2 - Cañas, A.
A2 - Casado, A.
A2 - Castejón-Pina, N.
A2 - Chaves, E. L.
A2 - del Molino, F.
A2 - del Toro, J.
A2 - Díaz, J. A.
A2 - Falgá, C.
A2 - Fernández-Capitán, C.
A2 - Font, L.
A2 - Gallego, P.
A2 - García-Bragado, F.
A2 - García-Ortega, A.
A2 - Gómez, V.
A2 - Skride, A.
N1 - RIETE Group - List of participating centers of the RIETE Group:
https://www.riete.org/info/centros_participantes/index.php
Publisher Copyright:
© 2015 International Society on Thrombosis and Haemostasis.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background: No studies have identified which patients with upper-extremity deep vein thrombosis (DVT) are at low risk for adverse events within the first week of therapy. Methods: We used data from Registro Informatizado de la Enfermedad TromboEmbólica to explore in patients with upper-extremity DVT a prognostic score that correctly identified patients with lower limb DVT at low risk for pulmonary embolism, major bleeding, or death within the first week. Results: As of December 2014, 1135 outpatients with upper-extremity DVT were recruited. Of these, 515 (45%) were treated at home. During the first week, three patients (0.26%) experienced pulmonary embolism, two (0.18%) had major bleeding, and four (0.35%) died. We assigned 1 point to patients with chronic heart failure, creatinine clearance levels 30-60 mL min -1 , recent bleeding, abnormal platelet count, recent immobility, or cancer without metastases; 2 points to those with metastatic cancer; and 3 points to those with creatinine clearance levels < 30 mL min -1 . Overall, 759 (67%) patients scored ≤ 1 point and were considered to be at low risk. The rate of the composite outcome within the first week was 0.26% (95% confidence interval [CI] 0.004-0.87) in patients at low risk and 1.86% (95% CI 0.81-3.68) in the remaining patients. C-statistics was 0.73 (95% CI 0.57-0.88). Net reclassification improvement was 22%, and integrated discrimination improvement was 0.0055. Conclusions: Using six easily available variables, we identified outpatients with upper-extremity DVT at low risk for adverse events within the first week. These data may help to safely treat more patients at home.
AB - Background: No studies have identified which patients with upper-extremity deep vein thrombosis (DVT) are at low risk for adverse events within the first week of therapy. Methods: We used data from Registro Informatizado de la Enfermedad TromboEmbólica to explore in patients with upper-extremity DVT a prognostic score that correctly identified patients with lower limb DVT at low risk for pulmonary embolism, major bleeding, or death within the first week. Results: As of December 2014, 1135 outpatients with upper-extremity DVT were recruited. Of these, 515 (45%) were treated at home. During the first week, three patients (0.26%) experienced pulmonary embolism, two (0.18%) had major bleeding, and four (0.35%) died. We assigned 1 point to patients with chronic heart failure, creatinine clearance levels 30-60 mL min -1 , recent bleeding, abnormal platelet count, recent immobility, or cancer without metastases; 2 points to those with metastatic cancer; and 3 points to those with creatinine clearance levels < 30 mL min -1 . Overall, 759 (67%) patients scored ≤ 1 point and were considered to be at low risk. The rate of the composite outcome within the first week was 0.26% (95% confidence interval [CI] 0.004-0.87) in patients at low risk and 1.86% (95% CI 0.81-3.68) in the remaining patients. C-statistics was 0.73 (95% CI 0.57-0.88). Net reclassification improvement was 22%, and integrated discrimination improvement was 0.0055. Conclusions: Using six easily available variables, we identified outpatients with upper-extremity DVT at low risk for adverse events within the first week. These data may help to safely treat more patients at home.
KW - Anticoagulant therapy
KW - Deep vein thrombosis
KW - Hospital
KW - Outcome
KW - Outpatients
KW - Upper extremity
UR - http://www.scopus.com/inward/record.url?scp=84935739964&partnerID=8YFLogxK
U2 - 10.1111/jth.13008
DO - 10.1111/jth.13008
M3 - Article
C2 - 25980766
AN - SCOPUS:84935739964
SN - 1538-7933
VL - 13
SP - 1274
EP - 1278
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 7
ER -